Cipla Current Affairs, GK & News
Precautionary vaccine jabs in India
The Government of India is to provide third dose of vaccine. This third dose has been named “precaution dose” or booster dose. About the precaution dose The health care workers, comorbid patients (people with severe medical conditions) and frontline workers are eligible to get the precaution dose. Five states in the country are to go ..
Month: Current Affairs - January, 2022
Category: Science & Technology Current Affairs
Topics: 2-DG • Biological E • booster dose • Cadila Pharmaceuticals • Cipla • Corbevax • COVAXIN • COVID-19 vaccines • Covishield • Covovax Vaccine • COWIN • Johnson and Johnson • Moderna • Molnupiravir • mRNA vaccine • Tocilizumab • ZyCov-D • Zydus Cadila
Zydus Cadila launched the cheapest generic version of Remdesivir in India
Zydus Cadila launched the cheapest generic version of Gilead Sciences’ antiviral drug Remdesivir in India to treat the deadly COVID 19 pandemic. The version has been launched after reports of a shortage of the drugs in the hospitals of the country. The price of drugs has been fixed as Rs 2800 per 100 mg vial. ..
Month: Current Affairs - August, 2020
Category: India Nation & States Current Affairs
Topics: Cipla • COVID-19 • Gilead Sciences • MERS • Remdesivir • SARS • Zydus Cadila
Cipla’s ‘Cipremi’ gets approval for Treatment of COVID-19 Patients in India
In its June 13th, 2020 guidelines for Clinical Management Protocol for COVID-19, the Union Health Ministry as a part of investigational therapy added ‘Remdesivir’ only for restricted emergency use. A week after, on 21st June 2020, Hetero and Cipla Pharmaceuticals were granted approval by the Drug Controller General of India for the production and marketing ..
Month: Current Affairs - June, 2020
Category: Science & Technology Current Affairs
Topics: Cipla • CIPREMI • COVID-19 • Drug Controller General of India • Gilead Science • Hetero Pharmaceuticals • Japan • Remdesivir • United States
Cipla acquires two US generic drug companies
Indian pharmaceutical giant Cipla Ltd. has acquired two US generic drug companies, InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. In this regard, Cipla has closed the transaction of the deal through its wholly-owned subsidiary, Cipla (EU) Ltd. Key facts These deals will allow Cipla to further strengthen its presence in the US pharmaceutical market is ..
Month: Current Affairs - February, 2016
Topics: Business • Cipla • Current Affairs 2016 • Economy • Pharmaceuticals Sector • United States
Cipla wins Rs 1170 cr tender from Global Fund to supply HIV drugs
Indian pharmaceutical giant, Cipla has been awarded $188.95 million (around Rs. 1,172 crore) Contract by Global Fund to supply ARV (anti-retroviral) drugs. Cipla has been selected as a Panel Supplier for a supplier partnership agreement. This contract is effective from 1 January 2015 and will run for a period of three years i.e. till 2018. ..
Month: Current Affairs - February, 2015
Topics: ARV (anti-retroviral) drugs • Cipla • Current Affairs 2016 • Global Fund